1. Search Result
Search Result
Results for "

1 mg aromatase Inhibitors

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

6

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14274
    Anastrozole
    2 Publications Verification

    ZD1033

    Cytochrome P450 Cancer
    Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM.
    Anastrozole
  • HY-148430

    Cytochrome P450 Cancer
    Aromatase-IN-2 is a potent aromatase inhibitor with an IC50 value of 1.5 µM .
    Aromatase-IN-2
  • HY-150775

    Cytochrome P450 Cancer
    Nonsteroidal aromatase inhibitor 1 (Compound 13h) is a nonsteroidal aromatase (CYP19A1) inhibitor (IC50=0.09 nM). Nonsteroidal aromatase inhibitor 1 has potential for breast cancer research . Nonsteroidal aromatase inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Nonsteroidal <em>aromatase</em> <em>inhibitor</em> 1
  • HY-144824

    Cytochrome P450 Monoamine Oxidase Neurological Disease Cancer
    Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and aromatase dual inhibitor with IC50s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer .
    Monoamine oxidase/Aromatase-IN-1
  • HY-162105

    Cytochrome P450 Endocrinology Cancer
    Aromatase-IN-3 (compound 7d) is an aromatase inhibitor with an IC50 of 54 nM. Through suppressing the conversion of androstenedione to oestrogen caused by aromatase, Aromatase-IN-3 exerts an appreciable tumor growth inhibitory activities against breast cancer cell lines, suggesting its usage for ER+ cancer research .
    Aromatase-IN-3
  • HY-14274S

    ZD1033-d12

    Isotope-Labeled Compounds Cytochrome P450 Cancer
    Anastrozole-d12 is the deuterium labeled Anastrozole. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM[1][2].
    Anastrozole-d12
  • HY-U00176

    Cytochrome P450 Metabolic Disease
    Org30958 is a potent aromatase inhibitor in vivo.
    Org30958
  • HY-N5012

    Pasakbumin A

    Phosphodiesterase (PDE) Endocrinology
    Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.
    Eurycomanone
  • HY-137931

    Others Cancer
    Testololactone is an aromatase inhibitor. Testololactone can be used for research of breast carcinoma .
    Testololactone
  • HY-13632
    Exemestane
    2 Publications Verification

    FCE 24304; EXE

    Cytochrome P450 Endocrinology Cancer
    Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane
  • HY-14247
    Fadrozole hydrochloride
    1 Publications Verification

    CGS 16949A; (Rac)-FAD286 hydrochloride

    Cytochrome P450 Endocrinology Cancer
    Fadrozole hydrochloride (CGS 16949A) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM.
    Fadrozole hydrochloride
  • HY-14247A
    Fadrozole
    1 Publications Verification

    CGS 16949A free base; (Rac)-FAD286

    Cytochrome P450 Cancer
    Fadrozole (CGS 16949A free base) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM.
    Fadrozole
  • HY-W739700

    d-Aminoglutethimide L-Tartrate

    Cytochrome P450 Inflammation/Immunology
    (R)-(+)-Aminoglutethimide (L-Tartrate) is an inhibitor of aromatase. (R)-(+)-Aminoglutethimide inhibits androstenedione with a Ki value of 0.3 μM .
    (R)-(+)-Aminoglutethimide L-Tartrate
  • HY-13632S

    FCE 24304-d2; EXE-d2

    Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane-d2 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].
    Exemestane-d2
  • HY-13632S2

    FCE 24304-d3; EXE-d3

    Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane-d3 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].
    Exemestane-d3
  • HY-W392925

    d-Aminoglutethimide

    Cytochrome P450 Cancer
    (R)-(+)-Aminoglutethimide is a potent and orally active aromatase inhibitor. (R)-(+)-Aminoglutethimide has the potential for the research of breast cancer .
    (R)-(+)-Aminoglutethimide
  • HY-13632S1

    Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane- 13C3 is the 13C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].
    Exemestane-13C3
  • HY-13632R
    Exemestane (Standard)
    2 Publications Verification

    FCE 24304(Standard); EXE (Standard)

    Cytochrome P450 Endocrinology Cancer
    Exemestane (Standard) is the analytical standard of Exemestane. This product is intended for research and analytical applications. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane (Standard)
  • HY-146688

    Cytochrome P450 Cancer
    SYN20028567 is an aromatase (CYP19) inhibitor with an IC50 of 9.4 nM. SYN20028567 can be used for breast cancer research .
    SYN20028567
  • HY-105375

    Cytochrome P450 Cancer
    FR 901537 is a potent and competitive aromatase inhibitor. FR 901537, a novel naphthol derivative, has the potential for breast cancer research .
    FR 901537
  • HY-105184

    Cytochrome P450 Endocrinology
    YM511 is a highly specific non-steroidal aromatase inhibitor. YM511 inhibits aromatase activities in microsomes from rat ovary and human placenta competitively (IC50s of 0.4 and 0.12 nM, respectively). YM511 slightly inhibits production of other steroid hormones. YM511 has the potential for suppressing estrogen-dependent action research without affecting serum levels of other steroid hormones .
    YM511
  • HY-105163

    MPV-2213ad

    Cytochrome P450 Endocrinology
    Finrozole (MPV-2213ad) is a nonsteroidal, orally active and competitive aromatase enzyme inhibitor. Finrozole can be used for urinary symptoms research .
    Finrozole
  • HY-18719B

    Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study .
    Endoxifen hydrochloride
  • HY-18719E

    Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .
    Endoxifen
  • HY-19599

    (+)-Vorozole; R83842

    Cytochrome P450 Cancer
    Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor . Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer .
    Vorozole
  • HY-14248
    Letrozole
    Maximum Cited Publications
    14 Publications Verification

    CGS 20267

    Cytochrome P450 Autophagy Cancer
    Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer .
    Letrozole
  • HY-W087008

    Cytochrome P450 Endocrinology Cancer
    7-Hydroxyflavanone is a potent inhibitor of aromatase (CYP19) activity with the IC50 of 65 μM. 7-Hydroxyflavanone exerts various biological effects, including anticarcinogenic, antioxidant and (anti-)estrogenic effects, and modula
    7-Hydroxyflavanone
  • HY-113986

    (R)-Fadrozole; (R)-CGS 16949A free base; FAD286

    Others Cardiovascular Disease
    Dexfadrostat ((R)-Fadrozole) is a potent nonsteroidal inhibitor . Dexfadrostat also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats. .
    Dexfadrostat
  • HY-N3246

    NO Synthase Inflammation/Immunology
    Morachalcone A is a naturally-occurring aromatase inhibitor (IC50=4.6 mM). Morachalcone A is also a plants metabolite with potential anti-inflammatory and anticancer activity. Morachalcone A inhibits Lipopolysaccharide (HY-D1056)-induced nitric oxide production .
    Morachalcone A
  • HY-18719ES

    Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen-d5 is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].
    Endoxifen-d5
  • HY-136063

    Fungal Cytochrome P450 Infection
    Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (Kd= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC50=0.92 μM) .
    Mefentrifluconazole
  • HY-14247B

    CGS 16949A hemihydrate; (Rac)-FAD286 hydrochloride hemihydrate

    Cytochrome P450 Endocrinology Cancer
    Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal aromatase inhibitor, with an IC50 of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC50 values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer .
    Fadrozole hydrochloride hemihydrate
  • HY-118178

    Cytochrome P450 Monoamine Oxidase Cardiovascular Disease
    LY43578 is an orally active aromatase inhibitor. LY43578 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC50 of 0.3 and 5 μΜ, respectively. LY43578 can be used for neurological disorder study .
    LY43578
  • HY-118407

    Cytochrome P450 Monoamine Oxidase Neurological Disease
    LY56110 is an orally active aromatase inhibitor. LY56110 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC50 of 2.5 and 11 μΜ, respectively. LY56110 can be used for neurological disorder study .
    LY56110
  • HY-B0845

    BTS 40542

    Fungal Estrogen Receptor/ERR Androgen Receptor Aryl Hydrocarbon Receptor Infection Endocrinology
    Prochloraz is an imidazole antifungal. Prochloraz is as an estrogen receptor (ER) and androgen receptor (AR) antagonist and an aromatase inhibitor with IC50 values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the aryl hydrocarbon receptor (AhR) having an EC50 of 1 μM .
    Prochloraz
  • HY-152250

    Cytochrome P450 Bacterial Infection
    Antibacterial agent 132 has anticandidal effects against C. parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) with MIC90 values of <0.06 μg/mL and 62.50 μg/mL, respectively. Antibacterial agent 132 inhibits aromatase enzyme with an IC50 of 0.047μM .
    Antibacterial agent 132
  • HY-14248S

    Isotope-Labeled Compounds Cytochrome P450 Autophagy Cancer
    Letrozole-d4 (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer[1][2][3].
    Letrozole-d4
  • HY-155493

    Cytochrome P450 Cancer
    CYP19A1/CYP11B2-IN-1 (Compound X21) is a potent and selective aromatase and aldosterone synthase dual inhibitor with IC50s of 2.3 nM and 29 nM for aromatase (CYP19A1) and aldosterone synthase (CYP11B2), respectively. CYP19A1/CYP11B2-IN-1 has excellent antiproliferative and pro-apoptotic activity against the cancer cell. CYP19A1/CYP11B2-IN-1 can be used for research of breast cancer .
    CYP19A1/CYP11B2-IN-1
  • HY-B0084
    Dienogest
    1 Publications Verification

    STS 557

    Progesterone Receptor Endocrinology
    Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE2 synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .
    Dienogest
  • HY-N0292
    Oleuropein
    1 Publications Verification

    Cytochrome P450 PPAR Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .
    Oleuropein
  • HY-136092

    Cytochrome P450 Neurological Disease Endocrinology
    Androsta-1,4,6-triene-3,17-dione is a lipophilic and specific aromatase inhibitor with a Ki of 0.18 μM. Androsta-1,4,6-triene-3,17-dione inhibits estrogen biosynthesis and shows antifertility effects. Androsta-1,4,6-triene-3,17-dione induces impairment of spatial memory .
    Androsta-1,4,6-triene-3,17-dione

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: